A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutation
Status:
Active, not recruiting
Trial end date:
2022-10-31
Target enrollment:
Participant gender:
Summary
This is a phase 1, multi-center, single-arm study to evaluate the pharmacokinetics(PK)/
pharmacodynamics(PD), safety, and clinical efficacy of orally administered Ivosidenib in
Chinese subjects with R/R AML with an IDH1 mutation.